BMSplus – the portal for health care professionals
Our Range of Topics at a Glance
Extensive media library
Access a wide range of resources, including webinars, podcasts, HCP materials, and patient brochures, all designed to support your professional needs.
Your BMS team
Dive into our disease areas: explore resources, research, and insights
News and recent approvals
Hepatocellular Cancer
April 2025 – OPDIVO® in combination with YERVOY® is now approved for the first-line treatment of adult patients with unresectable hepatocellular carcinoma (HCC).
Thoracic Cancer
March 2025 - Perioperative OPDIVO® according to CheckMate 77T is now approved for the treatment of adult patients with resectable (tumors ≥ 4 cm or positive lymph node involvement) non-small cell lung cancer (NSCLC) with PD-L1 tumor expression ≥ 1%.
Gastrointestinal Cancer
January 2025 - OPDIVO® in combination with YERVOY® is now approved for the first-line treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) unresectable or metastatic colorectal cancer.
Thoracic Cancer
December 2024 - OPDIVO® in combination with YERVOY® and 2 cycles of platinum-based chemotherapy is now approved for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults with no EGFR or ALK genomic tumor aberrations.
Genitourinary Cancer
August 2024 - OPDIVO® is now approved in combination with cisplatin/gemcitabine chemotherapy for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma with PD-L1 tumor expression ≥1%.
Gastrointestinal Cancer
March 2024 – OPDIVO® (nivolumab) in combination with chemotherapy containing oxaliplatin and fluoropyrimidine is indicated for the first-line treatment of adult patients with inoperable, locally advanced or metastatic gastric cancer, gastroesophageal junction cancer, and distal oesophageal adenocarcinoma with Combined Positive Score (CPS) PD-L1 expression ≥ 10.
05/2025 ONC-CH-2500053